CDXS logo

CODEXIS INC

CDXSNASDAQ
πŸ† #3514 by market capUS Equity
$1.64β–² $0.17 (+10.47%)
Live
1hβ–² 1.9%
24hβ–² 10.5%
7dβ–² 12.0%
14dβ–² 10.5%
30dβ–Ό 27.0%
1yβ–Ό 42.8%
🏦Market Cap
$176M
Small Cap
πŸ“ˆRevenue Growth (YoY)
+56.8%
High Growth
πŸ“ŠGross Margin
88.9%
High
πŸ’΅FCF Margin
25.1%
Strong
βš–οΈP/S Ratio
2.0x
Cheap
Otter Score
51
Weak

Trading Snapshot

Day Range
$1.62 – $1.66
52-Week Range
$0.96 – $3.87
Volume
$4.48B
Avg Volume
$5.15B
Shares Outstanding
107.6M
Next Earnings
Aug 30, 2026

Fundamentals Snapshot

Annual Revenue
$70M
Last Q Revenue
$15M
P/E Ratio
β€”
P/S Ratio
2.0x
EPS (TTM)
$-0.36
Dividend Yield
β€”

Why Investors Own CDXS

  • βœ“High-growth profile β€” revenue up +51.7% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 68% gross margin and 12% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$70Mβ–² +45.1% YoY
Gross Margin (TTM)
67.7%β–² +0.0% YoY
Operating Income (TTM)
$17Mβ–² +45.1% YoY
Free Cash Flow (TTM)
$8Mβ–² +45.1% YoY

About CODEXIS INC

Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening. The company also extends its expertise through biocatalyst screening and sophisticated protein engineering services. Central to its operations is the proprietary CodeEvolver protein engineering technology platform. This innovative platform is instrumental in crafting and delivering high-performance biocatalysts capable of driving chemical transformations, thereby significantly enhancing the efficiency and productivity of manufacturing processes. Beyond industrial applications, the CodeEvolver platform is also leveraged for identifying novel biotherapeutic drug candidates for targeted human diseases, as well as for developing enzymes essential for molecular biology research and in vitro diagnostic applications. Primarily serving pharmaceutical manufacturers, Codexis distributes its products through its dedicated direct sales and business development teams across the United States and Europe. Established in 2002, the company maintains its headquarters in Redwood City, California.

🦦

Otter Score Breakdown

β“˜
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
Overall Score
Weak
51/100

Analyst Price Target

β“˜
Average Target
$1.90
β–² +16.1% Upside
High Target$2.14
Low Target$1.50
Based on 16 analysts

Latest News & Updates